These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 35278845)
21. Cost-Effectiveness of Tumor Genomic Profiling to Guide First-Line Targeted Therapy Selection in Patients With Metastatic Lung Adenocarcinoma. Dong OM; Poonnen PJ; Winski D; Reed SD; Vashistha V; Bates J; Kelley MJ; Voora D Value Health; 2022 Apr; 25(4):582-594. PubMed ID: 35365302 [TBL] [Abstract][Full Text] [Related]
22. Comprehensive genomic profiling in advanced/metastatic colorectal cancer: number needed to test and budget impact of expanded first line use. Proudman D; DeVito NC; Belinson S; Allo MA; Morris ED; Signorovitch J; Patel AK J Med Econ; 2022; 25(1):817-825. PubMed ID: 35593483 [TBL] [Abstract][Full Text] [Related]
23. Real-world clinical and economic outcomes for patients with advanced non-small cell lung cancer enrolled in a clinical trial following comprehensive genomic profiling via liquid biopsy. Wiedower JA; Forbes SP; Tsai LJ; Liao J; Raez LE J Manag Care Spec Pharm; 2024 Jul; 30(7):660-671. PubMed ID: 38950156 [TBL] [Abstract][Full Text] [Related]
24. Real-World Impact of Comprehensive Genomic Profiling on Biomarker Detection, Receipt of Therapy, and Clinical Outcomes in Advanced Non-Small Cell Lung Cancer. Wallenta Law J; Bapat B; Sweetnam C; Mohammed H; McBratney A; Izano MA; Scannell Bryan M; Spencer S; Schroeder B; Hostin D; Simon GR; Berry AB JCO Precis Oncol; 2024 May; 8():e2400075. PubMed ID: 38754057 [TBL] [Abstract][Full Text] [Related]
25. Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC. Riess JW; Gandara DR; Frampton GM; Madison R; Peled N; Bufill JA; Dy GK; Ou SI; Stephens PJ; McPherson JD; Lara PN; Burich RA; Ross JS; Miller VA; Ali SM; Mack PC; Schrock AB J Thorac Oncol; 2018 Oct; 13(10):1560-1568. PubMed ID: 29981927 [TBL] [Abstract][Full Text] [Related]
26. Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice. Cho BC; Loong HHF; Tsai CM; Teo MLP; Kim HR; Lim SM; Jain S; Olsen S; Park K Curr Oncol; 2022 Mar; 29(3):2154-2164. PubMed ID: 35323374 [TBL] [Abstract][Full Text] [Related]
27. Comprehensive genomic profiling of Brazilian non-small cell lung cancer patients (GBOT 0118/LACOG0418). Mascarenhas E; Gelatti AC; Araújo LH; Baldotto C; Mathias C; Zukin M; Werutsky G; Pacheco P; Gomes R; de Castro G; Cordeiro de Lima VC Thorac Cancer; 2021 Mar; 12(5):580-587. PubMed ID: 33314759 [TBL] [Abstract][Full Text] [Related]
28. Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in Real-World Clinical Practice. Singh AP; Shum E; Rajdev L; Cheng H; Goel S; Perez-Soler R; Halmos B Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32375398 [TBL] [Abstract][Full Text] [Related]
29. Budget Impact Analysis of Comprehensive Genomic Profiling in Advanced Non-Small Cell Lung Cancer in Taiwan. Tsai YL; Chang CJ Value Health Reg Issues; 2023 May; 35():48-56. PubMed ID: 36863067 [TBL] [Abstract][Full Text] [Related]
30. Association of Timely Comprehensive Genomic Profiling With Precision Oncology Treatment Use and Patient Outcomes in Advanced Non-Small-Cell Lung Cancer. Yorio J; Lofgren KT; Lee JK; Tolba K; Oxnard GR; Schrock AB; Huang RSP; Brisbin L JCO Precis Oncol; 2024 Mar; 8():e2300292. PubMed ID: 38452312 [TBL] [Abstract][Full Text] [Related]
31. Changing the Therapeutic Landscape in Non-small Cell Lung Cancers: the Evolution of Comprehensive Molecular Profiling Improves Access to Therapy. Sabari JK; Santini F; Bergagnini I; Lai WV; Arbour KC; Drilon A Curr Oncol Rep; 2017 Apr; 19(4):24. PubMed ID: 28303491 [TBL] [Abstract][Full Text] [Related]
33. The Challenges and Opportunities of the Implementation of Comprehensive Genomic Profiling in Everyday Clinical Practice with Non-Small Cell Lung Cancer: National Results from Croatia. Čerina D; Krpina K; Jakopović M; Dedić Plavetić N; Seiwerth F; Tomić S; Radić J; Belac Lovasić I; Canjko I; Boban M; Samaržija M; Vrdoljak E Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444505 [TBL] [Abstract][Full Text] [Related]
34. Characteristics of Genomic Alterations in Pericardial Effusion of Advanced Non-small Cell Lung Cancer. He J; Hu X; Chen L; Liu Q; Jiang Y Front Genet; 2022; 13():850290. PubMed ID: 35646096 [No Abstract] [Full Text] [Related]
36. Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing. Schrock AB; Frampton GM; Herndon D; Greenbowe JR; Wang K; Lipson D; Yelensky R; Chalmers ZR; Chmielecki J; Elvin JA; Wollner M; Dvir A; -Gutman LS; Bordoni R; Peled N; Braiteh F; Raez L; Erlich R; Ou SH; Mohamed M; Ross JS; Stephens PJ; Ali SM; Miller VA Clin Cancer Res; 2016 Jul; 22(13):3281-5. PubMed ID: 26933124 [TBL] [Abstract][Full Text] [Related]
37. Impact of Comprehensive Genome Profiling on the Management of Advanced Non-Small Cell Lung Cancer: Preliminary Results From the Lung Cancer Cohort of the FPG500 Program. Vitale A; Mastrantoni L; Russo J; Giacomini F; Giannarelli D; Duranti S; Vita E; Nero C; D'Argento E; Pasciuto T; Giacò L; Di Salvatore M; Panfili A; Stefani A; Cancellieri A; Lococo F; De Paolis E; Livi V; Daniele G; Trisolini R; Minucci A; Margaritora S; Lorusso D; Normanno N; Scambia G; Tortora G; Bria E JCO Precis Oncol; 2024 Oct; 8():e2400297. PubMed ID: 39374480 [TBL] [Abstract][Full Text] [Related]
38. Molecular profiling and feasibility using a comprehensive hybrid capture panel on a consecutive series of non-small-cell lung cancer patients from a single centre. Mosteiro M; Azuara D; Villatoro S; Alay A; Gausachs M; Varela M; Baixeras N; Pijuan L; Ajenjo-Bauza M; Lopez-Doriga A; Teulé Á; Solanes A; Palmero R; Brenes J; Jové M; Padrones S; Moreno V; Cordero D; Matías-Guiu X; Lázaro C; Nadal E ESMO Open; 2023 Dec; 8(6):102197. PubMed ID: 38070435 [TBL] [Abstract][Full Text] [Related]
39. Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database. Singal G; Miller PG; Agarwala V; Li G; Kaushik G; Backenroth D; Gossai A; Frampton GM; Torres AZ; Lehnert EM; Bourque D; O'Connell C; Bowser B; Caron T; Baydur E; Seidl-Rathkopf K; Ivanov I; Alpha-Cobb G; Guria A; He J; Frank S; Nunnally AC; Bailey M; Jaskiw A; Feuchtbaum D; Nussbaum N; Abernethy AP; Miller VA JAMA; 2019 Apr; 321(14):1391-1399. PubMed ID: 30964529 [TBL] [Abstract][Full Text] [Related]
40. Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients. Paweletz CP; Sacher AG; Raymond CK; Alden RS; O'Connell A; Mach SL; Kuang Y; Gandhi L; Kirschmeier P; English JM; Lim LP; Jänne PA; Oxnard GR Clin Cancer Res; 2016 Feb; 22(4):915-22. PubMed ID: 26459174 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]